Emergent BioSolutions, National Institutes of Health, U.S. Department of Health and Human Services infectious news

EBS received a three-year contract from HHS for up to $447.7 million for the company's BioThrax anthrax vaccine. The contract includes $400 million to deliver 18.8 million doses for the strategic national stockpile, $34 million if FDA approves EBS's pending sBLA to extend the shelf life of BioThrax from three to four years, eligibility for $11.5 million in milestones to develop the vaccine as a post-exposure prophylactic, and $2.2 million for logistic services and support. The company expects to deliver about 6 million doses by year end. Since 1998, the U.S. government has received about 20 million doses of BioThrax. ...